Clinical trials: Antipsychotics
Schizophrenia, Schizoaffective Disorder
An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
The aim of this study is to evaluate the effectiveness, safety, and tolerability of metformin treatment in children and adolescents suffering from weight gain secondary to use of atypical antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder
- Trial name
- NCT00391261
- Testing
- Metformin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cambridge Health Alliance
Schizophrenia
Treatment for First-Episode Schizophrenia
This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
- Trial name
- NCT00000374
- Testing
- Olanzapine, Risperidone
- Where
- 2 sites in United States
- Volunteers
- 125 people
- Sponsor
- Northwell Health
Psychosis, Remission
Guided Dose Reduction of Antipsychotic in Patients With Psychosis in Remitted States
A 2-year prospective observational study comparing a group of patients in remitted states of psychosis undergoing guided antipsychotic dose reduction to a similar group of patients under maintenance antipsychotic treatment with…
- Trial name
- GDR (NCT03248180)
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia
A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)
This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia.
- Trial name
- NCT01235520
- Testing
- RO4917838
- Where
- 121 sites in United States, Argentina and 12 more
- Volunteers
- 595 people
- Sponsor
- Hoffmann-La Roche
Delirium, Impaired Cognition
The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study
The long-term objective of the MIND-USA (Modifying the Impact of ICU-Induced Neurological Dysfunction-USA) Study is to define the role of antipsychotics in the management of delirium in vulnerable critically ill patients.
- Conditions
- Delirium, Impaired Cognition, Long Term Psychologic Disorders
- Trial name
- MIND-USA (NCT01211522)
- Testing
- Haloperidol, Ziprasidone
- Where
- 16 sites in United States
- Volunteers
- 566 people
- Sponsor
- Vanderbilt University Medical Center
Schizophrenia
Influence of Vitamin D Supplementation on Serum BDNF Level and Cognitive Function in Schizophrenia
The objective of the study is to evaluate the influence of vitamin D supplementation on Serum Brain Derived Neurotrophic Factor level and cognitive function in schizophrenia treated with atypical antipsychotic.
- Trial name
- NCT03284294
- Testing
- Cholecalciferol
- Volunteers
- 40 people
- Sponsor
- Universitas Padjadjaran
Schizophrenia
Mitochondria and Schizophrenia: Effects of Antipsychotic Drugs
The investigators will investigate 1. the relationships between oxidative stress-, apoptosis-related markers, mitochondria DNA copy numbers and the clinical psychopathology of schizophrenia, including severity of positive and…
- Trial name
- NCT01479413
- Where
- Taiwan
- Volunteers
- 77 people
- Sponsor
- Chang Gung Memorial Hospital
Schizophrenia
A Trial to Assess the Antipsychotic Efficacy of ITI-007
The study will be conducted as a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.
- Trial name
- NCT02282761
- Testing
- ITI-007
- Where
- 11 sites in United States
- Volunteers
- 450 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Risperidone-induced Hyperprolactinemia
Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia
The purpose of this study is to determine whether calcium and vitamin D supplementation, over a nine-month period, optimizes bone mineralization in boys with risperidone-induced hyperprolactinemia.
- Trial name
- NCT00799383
- Testing
- Calcium and Vitamin D
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Chadi A. Calarge
Schizophrenia, Schizoaffective Disorders
An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment
The purpose of this study is to evaluate the efficacy and safety of long-acting risperidone microspheres (small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various…
- Trial name
- NCT00526877
- Testing
- Risperidone
- Where
- Taiwan
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
Obesity, Vitamin D Deficiency
Vitamin D Supplementation in Psychiatric Illnesses
Children and adolescents with psychiatric illnesses who are treated with medications called second generation antipsychotic agents (SGA) often gain excessive weight during their treatment with these medications.
- Conditions
- Obesity, Vitamin D Deficiency, Psychosis, Schizophrenia
- Trial name
- VDSS (NCT01004354)
- Testing
- Ergocalciferols
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia
A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia
The purpose of this study is to evaluate the long-term safety and tolerability and the maintenance of effectiveness of a slow, extended-release oral formulation of paliperidone administered once daily to patients diagnosed with…
- Trial name
- NCT00210769
- Testing
- paliperidone ER Oros
- Volunteers
- 203 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NSCLC Adenocarcinoma, Solid Tumor
Atamparib in Patients With Advanced Solid Tumors
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients…
- Trial name
- PARP7 (NCT07374419)
- Testing
- atamparib escalation levels, atamparib RP2D
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Nerviano Medical Sciences (Shanghai) Ltd.
Huntington Disease
Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride
Huntington's disease (HD) is autosomal dominant neurodegenerative disease, starting in average (with high variability) in the fourth decade.
- Trial name
- NEUROHD (NCT00632645)
- Testing
- Olanzapine, Xenazine, Tiapridal
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Schizophrenia, Psychotic Disorders
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document both short-term, as well as long-term efficacy and safety of a long-acting injectable formulation of risperidone, in comparison with olanzapine for the treatment of patients with…
- Trial name
- NCT00236457
- Testing
- risperidone
- Volunteers
- 629 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
APS-related Hyperprolactinaemia, Schizophrenia
Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine
Hyperprolactinaemia is a common side effect of some antipsychotics (APS), including some atypicals. Clinical consequences of hyperprolactinaemia are broad including amenorrhea, galactorrhea, tender breasts, gynecomastia and…
- Conditions
- APS-related Hyperprolactinaemia, Schizophrenia, Bipolar Disorder
- Trial name
- NCT00952757
- Where
- 6 sites in Spain
- Volunteers
- 35 people
- Sponsor
- Investigaciones Médicas Montejo S.L.
Schizophrenia
Antipsychotic Effects of Oxytocin
The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve symptoms in schizophrenia patients who have residual symptoms despite being on adequate treatment with…
- Trial name
- NCT01621737
- Testing
- Oxytocin
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- University of California, San Diego
Affective Disorder, Psychosis
Value of Gym-based Exercise Training for Young Adults Receiving Antipsychotic Medication: The Vega Trial
This is a multicentre, pragmatic, randomised controlled trial to estimate the effect of a 4-month gym-based exercise training program on 1) patient-rated personal recovery (primary outcome), 2) Health-related quality of life…
- Trial name
- Vega (NCT05461885)
- Testing
- Supervised exercise
- Where
- 4 sites in Denmark
- Volunteers
- 226 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Alzheimer Disease, Dementia Alzheimers
An Electronic Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions
The goal of this study will be to design, implement and test the impact of a quality improvement (QI) intervention that uses an EHR CDS tool among physicians newly ordering an antipsychotic medication for older adults with ADRD.
- Conditions
- Alzheimer Disease, Dementia Alzheimers, Dementia of Alzheimer Type
- Trial name
- NCT04851691
- Testing
- EHR CDS, Usual Care
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- University of California, Los Angeles